Cutting Edge Applied Research in Life Sciences and Biotechnology also in Biopharma.
Newsletter
BIOLABS works in a broad range of fields that encompass multidisciplinary approaches ranging from basic, technological to clinical and translational research, from the development of complex biopharmaceuticals and novel therapies to areas in food and health, including nutraceuticals development and agro-forestry.
Significant advances in the increased therapeutic efficacy of viral vectors for gene delivery have stimulated a major interest in the development and commercialization of such therapeutic products. Of the gene therapy products in development, recombinant Adeno-Associated Virus (AAV) based vectors are currently the most widely used. The promise and potential of this technology are perhaps best exemplified by the market authorization of three commercial gene therapies Glybera, Luxturna® and, most recently, Zolgensma®.
Current industrial bioprocesses for the production of virus based biopharmaceuticals are still anchored in technologies established decades ago, including the use of embryonated eggs for vaccines. In this very traditional industry, innovation is slow. The reasons for this are various: high safety regulations and development costs, no acceptance of side effects, and a conservative nature of the industry dominated by a few large companies, meaning there is less economic incentive to develop new vaccines and virus based manufacturing processes.
Green technology for plant-based food (short named GreenPlantFood) is a collaborative project (KSP 319049) to meet challenges in society and industry financed by The Norwegian Research Council and the Food Industry. A shift towards increased use of plant food has positive effects on health and environment . To actually achieve this, there is a strong need to find and develop new, healthy, and attractive plant-based food products.
